Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

INVESTOR PRESENTATION March 2025 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth opportunities, a ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $17.6 million, representing a 3.8% increase compared to Q4 2023, marking the first instance of single-digit revenue growth since the COVID-19 pandemic [7][31] - Full-year revenue for 2024 reached $69.3 million, a 19% increase year-over-year [31] - Gross margin for Q4 was 64%, down from 68% in the prior year, primarily due to higher expenses related to excess and obsolete inventory [32] Business Line Data and Key Metrics Changes - OviTex revenue grew 17% for the full year, with unit sales increasing by 28% in Q4 and 33% for the year [31][32] - PRS revenue grew 21% for the full year, with unit sales increasing by 11% in Q4 and 31% for the year [31][32] Market Data and Key Metrics Changes - The company faced external headwinds, including a hurricane that impacted surgical volumes in key regions, particularly in the Southeast [10][11] - The shortage of IV fluids due to the hurricane affected elective surgeries, contributing to lower surgical volumes [10][11] Company Strategy and Development Direction - The company is implementing a revised commercial strategy, focusing on a team-based sales approach with territory managers and account specialists [12][14] - There is an emphasis on expanding the product portfolio and capturing market share in hernia repair and plastic reconstructive surgery (PRS) [18][19] - The company plans to launch larger-sized versions of existing products and a new long-term resorbable alternative for hernia products in 2025 [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in Q4 but expressed optimism for 2025, citing a strong commercial strategy and anticipated product launches [12][38] - The company expects revenue growth of 23% to 27% in 2025, with a target range of $85 million to $88 million [34][36] Other Important Information - The company ended 2024 with $52.7 million in cash and cash equivalents, indicating a strong liquidity position [34] - Management highlighted the importance of clinical validation and educational outreach to enhance product adoption [22][24] Q&A Session Summary Question: Follow-up on territory manager departures - Management reported losing 11 territory managers in Q4 due to unplanned departures, which significantly impacted performance [43][44] Question: Outlook for 2025 regarding unit versus ASP expectations - Management indicated that the introduction of new products may lead to lower average selling prices (ASP) in some areas, but they expect ASP stability in PRS [52][56] Question: Confidence in reaching breakeven with existing liquidity - Management expressed confidence in achieving profitability, citing flat operating expenses and revenue growth [60][62] Question: Revenue guidance and sales ramp for 2025 - Management expects a typical seasonal ramp-up in revenue throughout 2025, with a strong start in Q1 [68][70] Question: Compensation strategies to retain top performers - Management has enhanced the compensation plan to retain top talent and mitigate the risk of poaching [126][128]

分组1 - TELA Bio, Inc. reported a quarterly loss of $0.23 per share, which is an improvement from a loss of $0.53 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $17.65 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 24.25%, but showing a slight increase from $17 million in the same quarter last year [2] - TELA Bio shares have declined approximately 21.9% since the beginning of the year, contrasting with the S&P 500's decline of 3.5% [3] 分组2 - The earnings outlook for TELA Bio is mixed, with the current consensus EPS estimate for the coming quarter at -$0.30 on revenues of $21 million, and -$0.66 on revenues of $94.1 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which TELA Bio belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook [8] - TELA Bio has surpassed consensus EPS estimates only once in the last four quarters, indicating challenges in meeting market expectations [1][2]

"Our team delivered 19% revenue growth in 2024, and we saw multiple record-high sales months throughout the year. Our fourth quarter results fell short of our expectations due to a confluence of disruptions, some of which we believe are transient and others that have already been redressed. Despite these challenges, the overall opportunity for substantial value creation from current levels remains intact." said Antony Koblish, co-founder, President, and Chief Executive Officer of TELA Bio. "We believe our O ...

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand f ...

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Co ...

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 36th Annual Healthcare Conference at 12:00 pm ET on December 3rd, 2024. Interested parties can access the live and archived webcast at ir.telabio.com. A ...

TELA Bio, Inc. (NASDAQ:TELA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earning ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-------------------------------------------------------------------------------------|------------------------------------------------------------ ...